Farallon Capital Urges Exelixis Shareholders to Support Change by Electing Its Three Highly Qualified Director Candidates

Files Definitive Proxy Materials and Sends Letter to Exelixis Shareholders


Encourages Shareholders to Show that the Status Quo Cannot Continue by Voting to Elect All Three of Farallon’s... | May 3, 2023

Related Keywords

United States ,New York ,American ,Tomas Heyman ,Neurocrine Biosciences ,David Johnson ,Tom Heyman ,Lance Willsey ,Michael Morrissey ,Robert Oliver ,Bob Oliver ,Dave Johnson ,Ineffective Compensation Program ,American Society Of Clinical Oncology ,Alnylam Pharmaceuticals ,Exchange Commission ,Alkermes ,Exelixis Inc ,Jazz Pharmaceuticals ,Management Team Have Led To This Underperformance ,Ionis Pharmaceuticals ,Johnson ,Bloomberg ,Mackenzie Partners Inc ,Nasdaq ,Farallon Capital Management ,Fellow Exelixis Shareholders ,Capital Partners ,Nasdaq Biotech Index ,Exelixis Board ,Annual Meeting ,Has Failed ,Deliver Shareholder ,Nasdaq Biotech ,Management Team Have Led ,Capital Allocation Strategy ,Capital Allocation ,Inefficient Balance Sheet ,Achieve Stated Targets ,Board Refreshment ,Board Alignment ,While Exelixi ,Compensation Program ,Chief Executive Officer Michael Morrissey ,Exelixis Has Been ,Global Head ,Business Development ,Janssen Pharmaceuticals ,Otsuka America Pharmaceutical ,American Society ,Clinical Oncology ,Exelixi Board ,Farallon Nominees ,Capital Management ,United States Securities ,Mackenzie Partners ,Biomarin Pharmaceutical ,Blueprint Medicines ,Emergent Biosolutions ,Horizon Therapeutics ,Sarepta Therapeutics ,Exelixis ,Nc Stock Exchange ,News ,Information ,Press Release ,Files ,Efinitive ,Proxy ,Materials ,End ,Ends ,Setter ,O ,Shareholders ,Show ,Hat ,The ,Status ,Duo ,Cannot ,Ontinue ,Y ,Voting ,Elect ,Wall ,Three ,F Exel Us30161q1040 ,